Oragenics Inc. (OGEN) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Oragenics, Inc. (OGEN) - corporate logo

The daily price chart for Oragenics, Inc. (OGEN) reflects an EV/EBITDA ratio of 0.00. Oragenics, Inc. (OGEN) promotes anti-infection agents and nasal vaccines, partnering with biotech centers to accelerate trials and attract buyers. The business remains independent of market cycles, relying solely on the success of its tests. Currently, the company is deploying capital toward research and development, relying entirely on external investments.

Oragenics Inc. - OGEN Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for Oragenics Inc. (OGEN)

- current price and projected stock value:
Stock Price Oragenics|OGEN - Analyst Median Target
- market capitalization details:
Market Value Oragenics, Inc.|OGEN - Business Value
- book value of equity indicators:
Book Value per Share Oragenics|OGEN - Net Asset Value|Market Capitalization to Book Value Ratio oragenics.com|OGEN - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Oragenics, Inc.|OGEN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Oragenics, Inc.|OGEN - Company Cumulative Indebtedness|Debts to Book Capitalization Oragenics, Inc.|OGEN - Long-Term Debt Volume|Company Short-Term Debt Oragenics|Quick Liquidity oragenics.com
- financial results and valuation multiples details:
OGEN - Company Profit|Expected Profit Oragenics, Inc.|OGEN - Business Payback Period|Future Price to Earnings Oragenics|OGEN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oragenics, Inc.|OGEN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Oragenics|OGEN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth oragenics.com|OGEN - Net earnings per share change in current year|Earnings growth forecast for next year Oragenics, Inc.
General company analysis:Oragenics OGEN
Product sample of oragenics.com

Oragenics, Inc. (OGEN) development of breakthrough intranasal therapies requires significant capital expenditures and debt load management. The EV/EBITDA metric compares the total enterprise value, including debt, with operating profit before interest, taxes, depreciation, and amortization, revealing the actual value of the assets. Analyzing the EV/EBITDA ratio of Oragenics, Inc. (OGEN) across a financial timeline allows investors to avoid overpaying for biotechnological potential by promptly identifying points of market capitulation.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio Moderna Therapeutics (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (tarsusrx.com) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - EV/EBITDA Multiple|Company Value to EBITDA Scynexis SCYX|EV/EBITDA Multiple ANTX|Enterprise Value to EBITDA Ratio polypid.com PYPD|LakeShore Biopharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ITRM (Iterum Therapeutics PLC)|BiomX Ltd - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Soligenix, Inc. SNGX|60degreespharma.com (SXTP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA opgen.com (OPGN)